New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) ...

CAMBRIDGE, MA, USA; ROTTERDAM, The Netherlands and SUZHOU, China I 8, 2024 I Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical ...

Late-Breaker Poster Presentation to occur at the 39th Annual Society for Immunotherapy of Cancer (SITC) conference on November 9th, 2024 - ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

“Immunotherapy and personalized therapy has transformed cancer treatment. However, there is still a dire need for new innovative therapies. We believe that AM003 — as a new class of individualized ...

REDMOND, WA, USA I November 8, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational ...

First-in-human randomized clinical trial demonstrates safety and tolerability of MD-18, Radella’s novel lead asset from its platform targeting cardiometabolic ...

SHANGHAI, China I November 8, 2024 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, showcased the “Preclinical Development of 7MW4811, an Mtoxin™ (MF6)-based ...

LOS ANGELES, CA, USA I November 8, 2024 I Nammi Therapeutics, Inc. (Nammi), a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC) and Nammisome ...

PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...

November 04, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...

Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody ...